Clinical trial NCT02746237: Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Official title: A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pulmonary Arterial Hypertension
Keywords: Serotonin
Pulmonary Arterial Hypertension
Pharmacokinetics
Phase 1
Healthy Volunteers
Lead sponsor: Karos Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2016-04-21
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.

Detailed description: The purpose of this study is to explore the safety, tolerability, pharmacokinetics (PK), and cardiac conduction effects of single and multiple ascending doses of KAR5585 in healthy adults. Food effect will also be evaluated after a single-dose administration.

Eligibility criteria: Inclusion Criteria:

* Subject is able to read, write, and comprehend English at a sufficient level to understand study-related materials
* Subject is able to provide written informed consent and to comply with all study requirements and restrictions
* Subject is male or female and aged 18 to 65 years, inclusive, at the time of informed consent
* Subject is in good health as determined by the PI based on detailed medical history, physical examination, vital signs, clinical laboratory tests, ECGs, and other pre-dose evaluations
* Subject agrees to use a medically acceptable form of birth control from CRU admission until at least 30 days (female subject) or 90 days (male subject) after the last dose of study drug. Males will also not donate sperm from CRU admission until at least 90 days after the last dose of study drug. If a subject is not sexually active but becomes active during study participation, the subject agrees they and their partner will use a medically accepted form of contraception for the time specified. Medically acceptable forms of contraception are:

  * FDA-approved female hormonal contraceptives used consistently for 2 or more cycles before Screening, including oral contraceptives, intrauterine device (IUD), medroxyprogesterone acetate injection (Depo Provera®), hormonal implant (Norplant®, Implanon®, Nexplanon®), and vaginal ring (NuvaRing®)
  * Male condom plus spermicide
  * Male condom plus contraceptive sponge, foam, or jelly
  * Female condom plus spermicide
  * Diaphragm with spermicide plus male condom
  * Cervical cap with spermicide plus male condom
  * Surgical sterilization of the subject or partner (vasectomy for males, hysterectomy or bilateral oophorectomy for females)
  * Abstinence
* If female, subject agrees that a serum pregnancy test (\[β hCG\] beta human chorionic gonadotropin ) will be performed at Screening, on Day 2 (CRU admission), and at the last study visit and negative test results at Screening and CRU admission are required to be considered for study participation
* Subject has a body mass index (BMI) of 20 to 35 kg/m2, inclusive, and body weight \< 120 kg at Screening

Exclusion Criteria:

* Subject currently uses tobacco or nicotine-containing products or has used such products within 6 months before CRU admission
* Subject has history or current evidence of any clinically significant cardiac, endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the PI
* Subject has a history of cancer within 5 years before CRU admission (excluding non-melanoma skin cancer)
* Subject has a history of autonomic dysfunction (eg, history of repeated dizziness, fainting, or symptomatic orthostatic hypotension)
* Subject has a history of risk factors for torsades de pointes, including unexplained syncope, known long QT syndrome, heart failure, myocardial infarction, angina, OR clinically significant abnormal laboratory assessments including hypokalemia, hypomagnesemia, or hypercalcemia OR has a family history of long QT syndrome or Brugada syndrome
* Subject has 1 or more clinically significant abnormal laboratory test values (as determined by the PI)
* Subject has an uninterpretable or abnormal screening ECG indicating a second- or third-degree atrioventricular block, or 1 or more of the following: QRS interval (ventricular depolarization) \> 110 msec; a PR interval (atrioventricular conduction) \> 220 msec, or QTc (corrected QT interval) of ≥ 450 msec (for male) or ≥ 470 msec (for female) or any rhythm other than sinus rhythm that is interpreted by the PI or a qualified designee to be clinically significant
* Subject has a resting heart rate (HR) of \< 40 beats/min or \> 90 beats/min at Screening or on CRU admission
* Subject has a sustained supine systolic blood pressure (BP) \> 155 or \< 90 mm Hg or a supine diastolic BP \> 95 or \< 50 mm Hg at Screening or upon CRU admission. Blood pressure in the supine position may be retested once and 'sustained' is defined as the parameter (either systolic or diastolic BP) being outside the stated limits at both assessments.
* Subject participates in another clinical trial or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, before CRU admission
* Subject has a history of alcohol or drug abuse or dependence within 12 months before CRU admission, as determined by the PI
* Subject has a clinically significant infection within 3 months before CRU admission, as determined by the PI
* Subject has any condition that, in the opinion of the PI, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study
* Subject has a positive urine screen for prohibited drugs (cocaine, cannabinoids, nicotine \[urine cotinine is the detection mechanism for nicotine\], opiates, barbiturates, amphetamines, and benzodiazepines) or positive urine test for alcohol
* Subject has a positive blood screen for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibody at the Screening Visit
* Subject has had a known or suspected hypersensitivity or idiosyncratic reaction to the cellulose used in the placebo to be used in this study
* Subject has donated blood or any blood products within 3 months before Screening or plans to donate blood during or within 3 months after study completion
* Subject consumes an excessive amount of caffeine daily, defined as \> 4 cups of coffee or equivalent per day. Subjects will abstain from caffeine consumption for 48 hours before dosing and while confined to the CRU.
* Subject has consumed or will consume any concomitant therapy; prescription or over-the-counter (OTC) medication; or nutritional, herbal, or vitamin supplements other than contraceptives (eg, oral, systemic) and ibuprofen (only if needed, maximum 2.4 g/day) from 14 days or 5 half-lives (whichever is longer) before dosing and while confined to the CRU
* For Part 2 only: Subject has consumed any food, juice, beverage, or medication (prescription or non-prescription) containing acetaminophen, alcohol, avocado, banana, caffeine, eggplant, kiwi fruit, nut (hickory nut, pecan, walnut), pineapple, plum, or tomato products within 48 hours before CRU admission

Primary outcomes:
measure: Number of participants with abnormal physical exam results
timeFrame: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
measure: Number of participants with abnormal hematology values
timeFrame: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
measure: Number of participants with abnormal electrocardiogram results
timeFrame: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
measure: Number of participants with abnormal clinical chemistry values
timeFrame: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
measure: Number of participants with abnormal urinalysis values
timeFrame: From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses
Secondary outcomes:
measure: Plasma area under the curve (AUC0-24) of prodrug KAR5585 and active inhibitor KAR5417 from time zero to 24 hours after dosing
timeFrame: From 0-24 hours on Days 1, 7 and 14
measure: Time to reach maximum observed plasma concentration (Tmax) of prodrug KAR5585 and active inhibitor KAR5417
timeFrame: From 0-24 hours on Days 1, 7 and 14
measure: Plasma terminal elimination half- life (T1/2) of prodrug KAR5585 and active inhibitor KAR5417
timeFrame: From 0-24 hours on Days 1, 7 and 14
measure: Apparent volume of distribution (Vz/F) of prodrug KAR5585 and active inhibitor KAR5417
timeFrame: From 0-24 hours on Days 1, 7 and 14
measure: Maximum peak concentration (Cmax) of prodrug KAR5585 and active inhibitor KAR5417
timeFrame: From 0-24 hours on Days 1, 7 and 14
measure: Serum levels of serotonin (ng/mL)
timeFrame: Days 1, 7 and 14
measure: Urinary levels of 5-hydroxyindoleacetic acid(mg/24 hrs)
timeFrame: From 0-24 hours on Days 1, 7 and 14
measure: Urinary levels of creatinine (gm/24 hrs)
timeFrame: From 0-24 hours on Days 1, 7 and 14
measure: Urinary levels of 5-hydroxyindoleacetic acid normalized to creatinine (mg/gm)
timeFrame: From 0-24 hours on Days 1, 7 and 14
measure: Plasma levels of 5-hydroxyindoleacetic acid (ng/mL)
timeFrame: Days 1, 7 and 14
measure: Plasma area under the curve (AUC0-24) of prodrug KAR5585 and active inhibitor KAR5417 from time zero to 24 hours after dosing
timeFrame: From 0-24hrs on Days 1, 7 and 14
measure: Time to reach maximum observed plasma concentration (Tmax) of prodrug KAR5585 and active inhibitor KAR5417
timeFrame: From 0-24hrs on Days 1, 7 and 14
measure: Plasma terminal elimination half-life (T1/2) of prodrug KAR5585 and active inhibitor KAR5417
timeFrame: From 0-24hrs on Days 1, 7 and 14
measure: Apparent volume of distribution (Vz/F) of prodrug KAR5585 and active inhibitor KAR5417
timeFrame: From 0-24hrs on Days 1, 7 and 14
measure: Maximum peak concentration (Cmax) of prodrug KAR5585 and active inhibitor KAR5417
timeFrame: From 0-24hrs on Days 1, 7 and 14
Other outcomes:
Locations:
city: West Bend
country: United States
facility: Spaulding Clinical
state: Wisconsin
Study officials:
affiliation: Spaulding Clinical
name: Carlos Sanabria, MD
role: PRINCIPAL_INVESTIGATOR
References: